Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Could Be Replaced With “Targeted Approval” – Manhattan Institute

Executive Summary

The need for Phase III clinical trials would be reduced if sponsors use validated biomarkers in Phase II studies under a Manhattan Institute proposal

You may also be interested in...

Novartis Proposes Two-Phase Drug Development Model, Staged Approval

Novartis is advocating a two-phase drug development paradigm based on "models of disease.

Warfarin Dosing Biomarkers Could Be Model For Genetic Tests In Labeling

The development of standards for a warfarin dosing biomarker under a collaboration with the C-Path Institute could pave the regulatory pathway for markers involving other therapeutic agents

Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood

Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts